Search Result

Results for "

Antibiotic screening

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Bacterial (2) Biochemical Assay Reagents (1) Caspase (2) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (1)
Oligonucleotides:	siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Oligonucleotides

Targets Recommended: Antibiotic

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113945

Abbeymycin	Antibiotic Bacterial	Infection
Abbeymycin is an *antibiotic* derived from the actinobacterium Streptomyces sp. AB-999F-52. Abbeymycin is a specifically acting antibiotic with antimicrobial activity, primarily targeting anaerobic bacteria. Abbeymycin is employed in research concerning antibiotic discovery and screening .

HY-122328

Flambamycin	Antibiotic Bacterial	Infection
Flambamycin is an antibiotic found in Streptomyces hygroscopicus DS 23230 strain, active against Gram-positive and Gram-negative cocci and some Gram-positive rods. Flambamycin can be used in research on antibiotic screening .

HY-158820

Cosdosiran QPI-1007	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-158820A

Cosdosiran sodium QPI-1007 sodium	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran sodium is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-E70364

IgdE protease	Biochemical Assay Reagents	Inflammation/Immunology
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .

HY-117204

AA-57	Antibiotic	Infection
AA-57 is an acidic lipophilic antibiotic isolated from the fermentation broth of Actinomycetes strain AA-57. The AA-57 strain was isolated from a soil sample collected in Koriyama City, Fukushima Prefecture, Japan. AA-57 has antibacterial properties against Gram-positive bacteria, Gram-negative bacteria, and acid-fast bacteria. AA-57 was discovered by screening actinomycete cultures for antibacterial properties. AA-57 exhibits significant antibacterial activity and has inhibitory effects against a variety of bacteria. The discovery of AA-57 provides new possibilities for antibacterial therapy.

Cat. No.	Product Name

HY-L067

Antibiotics Library	682 compounds
Antibiotics are types of antimicrobial products used for the treatment and prevention of bacterial infections. Antibiotics can kill or inhibit bacterial growth. Although the target of an antibiotic is bacteria, some antibiotics also attack fungi and protozoans. However, antibiotics rarely have an effect on viruses. The major mechanism underlying antibiotics is the inhibition or regulation of enzymes involved in cell wall biosynthesis, nucleic acid metabolism and repair, protein synthesis, or disruption of membrane structure. Many of these cellular functions targeted by antibiotics are most active in multiplying cells. Since there is often overlap in these functions between prokaryotic bacterial cells and eukaryotic mammalian cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents. MCE supplies a unique collection of 682 antibiotics, including penicillins, cephalosporins, tetracyclines, macrolides, etc. MCE Antibiotics Library is a useful tool for anti-bacterial or anti-cancer drugs discovery.

Antibiotics Library

682 compounds

Antibiotics are types of antimicrobial products used for the treatment and prevention of bacterial infections. Antibiotics can kill or inhibit bacterial growth. Although the target of an antibiotic is bacteria, some antibiotics also attack fungi and protozoans. However, antibiotics rarely have an effect on viruses. The major mechanism underlying antibiotics is the inhibition or regulation of enzymes involved in cell wall biosynthesis, nucleic acid metabolism and repair, protein synthesis, or disruption of membrane structure. Many of these cellular functions targeted by antibiotics are most active in multiplying cells. Since there is often overlap in these functions between prokaryotic bacterial cells and eukaryotic mammalian cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents.

MCE supplies a unique collection of 682 antibiotics, including penicillins, cephalosporins, tetracyclines, macrolides, etc. MCE Antibiotics Library is a useful tool for anti-bacterial or anti-cancer drugs discovery.

HY-L155

Mitochondrial Toxicity Compound Library	483 compounds
Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity. MCE contains 483 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.

Mitochondrial Toxicity Compound Library

483 compounds

Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity.

MCE contains 483 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.

HY-L076

Drug-Induced Liver Injury (DILI) Compound Library	1,426 compounds
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug. DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver. MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1,426 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Drug-Induced Liver Injury (DILI) Compound Library

1,426 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1,426 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Cat. No.	Product Name	Category	Target	Chemical Structure